Samsung Bioepis transfers eye care biosimilar sales rights to US firm

Samsung Bioepis has transferred the commercial responsibility of its two ophthalmic biosimilars in the United States to a local pharmaceutical firm, the biotech firm said Friday. Samsung Bioepis entered into a license, development and commercialization agreement (DCA) with Harrow, a U.S. eye care drug specialist, transferring the commercialization rights of the former’s ophthalmology biosimilar drugs Byooviz and Opuviz in the U.S. Currently, the U.S. commercial rights for the two drugs are held by Biogen, a former stakeholder of Samsung Bioepis. Harrow’s commercial license will become effective upon completion of the transition of commercial rights from Biogen back to Samsung Bioepis, which is expected to be completed by the end of 2025. In October 2024, Biogen notified Samsung Bioepis of its decision to terminate the 2019 DCA on the two drugs within the U.S. and Canada. Biogen held 50 percent less one share of Samsung Bioepis, but ended the shareholding relationship in 2022 by selling its stake to Samsung Biologics. Byooviz was approved by the U.S. Food and Drug Administration (FDA)Weiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times